the medication increases the number of satisfying sexual events per month by about one half over placebo from a starting point of about two to three the certainty of the estimate is low the side effects of dizziness sleepiness and nausea occur about three to four times more often development by boehringer ingelheim was halted in october 2010 following a negative evaluation by the u s food and drug administration the rights to the drug were then transferred to sprout pharmaceuticals which achieved approval of the drug by the us fda in august 2015 hsdd was recognized as a distinct sexual function disorder for more than 30 years but was removed from the diagnostic and statistical manual of mental disorders in 2013 and replaced with a new diagnosis called female sexual interest arousal disorder fsiad flibanserin is used for hypoactive sexual desire disorder among women those receiving flibanserin report a 0 5 increase compared to placebo in the number of times they had satisfying sexual events in those on flibanserin it rose from 2 8 to 4 5 times a month while women receiving placebo reported also an increase of satisfying sexual events from 2 7 to 3 7 times